Objective-To compare the first admission rates for schizophrenia in Conclusions-British and French psychiatrists use different diagnostic criteria and contrasting methods oftreatment for schizophrenia. Differences in diagnostic criteria probably contribute towards the disparity in administrative incidence rates and time trends for schizophrenia in the two countries. Doctors in the European Community can now work in any country. Further work is needed to ensure psychiatrists are talking a common language.
Introduction
Economic and political union are high on the agenda in the European Community, and medical doctors can work in any member state. Nevertheless, widespread differences in medical practice exist in Europe, ranging from the diagnosis and treatment of low blood pressure' to the treatment of testicular cancer.2 Psychiatric practice seems to have been particularly affected by the traditional divide between Anglo Saxon empiricism and continental rationalism-between trying to reach the truth through experiment and trying to reach it through ideas. This is perhaps most apparent in the psychiatric traditions of the United Kingdom and France.
Psychoanalysis, focusing on "unconscious" conflicts, has been much more influential in France,3 whereas in the United Kingdom psychiatry has enjoyed a close relation with physical medicine. In the United Kingdom the old diagnostic dichotomy between affective and schizophrenic psychoses has survived, with the category of "other psychoses" accommodating those psychotic disorders not considered to belong to BMJ voLuME 307 21 AUGUST 1993
The ratio of observed to expected events in France was then used to multiply the English rates. Psychological mechanism is dissociation of psychological experience ance levels in all but five of the 38 statements (table II) . Not infrequently the mean scores indicated that psychiatrists in the two countries-on averageactually disagreed with each other. French psychiatrists reserved the label schizophrenia for disorders with an onset before the age of 45, a chronic course, and poor outcome, with dissociation and discordance as the key symptoms. In the United Kingdom, good outcome and late onset cases tended to be included as well as the delusional disorders. Schneider's first rank symptoms were considered core features. French psychiatrists favoured psychoanalytically orientated aetiological statements, such as absence of the paternal image and maternal ambivalence, while the British scored high on items postulating neurodevelopmental and genetic causation. There were striking differences over the role of family dynamics and parental factors in the causation of schizophrenia; French psychiatrists gave these much more importance than their British colleagues.
Different attitudes to management were also observed. The British sample disagreed with psychoanalytical statements in favour of biological and behavioural theory. In France psychiatrists saw a more important role for the hospital than in Britain, but the latter were more frustrated with the perceived inadequacy of community services. French psychiatrists had more distinctive indications for different antipsychotic agents, and probably as a consequence showed a preference for treating patients with two antipsychotic agents-which was disapproved of by the British.
Adjustment for sex of psychiatrist, pschiatric experience, and recent contact with a schizophrenic patient did not affect the AngloFrench differences. Comparison of French private and public psychiatrists showed significant differences in only three of the 38 statements, but these differences remained small in comparison with those between the French and British samples.
Discussion
The epidemiological study illustrated a disparity between incidence rates in England and France.
French rates were much higher, especially before the age of 45, and longitudinal trends in the two countries were in opposite directions over the period under investigation. The questionnaire study showed differences between British and French psychiatrists about the aetiology, diagnosis, and management of schizophrenia.
Data on first admissions and their longitudinal trends do not necessarily reflect real changes in the incidence of a disorder such as schizophrenia." 14 Though the observed differences might reflect differences in real incidence," they might also reflect differences in factors such as arrangements for community care and diagnostic bias.
Like most west European countries, both the United Kingdom and France have pursued the policy of community care over the past 25 years. Between 1972 and 1982 the number of psychiatric beds per 100 000 population decreased from 250 to 227 (a possible underestimate) in France, and from 280 to 217 in the United Kingdom.'6 Though these figures suggest that the bed numbers may have decreased more rapidly in the United Kingdom, this difference is not large and can explain neither the divergence in male and female trends in France nor the fact that rates in France were rising while they were falling in England.
Diagnostic divergence, on the other hand, probably does contribute to the contrasting incidence rates in the two countries. According to our survey, French psychiatrists are reluctant to diagnose shizophrenia after the age of 45. This is corroborated by the epidemiological findings, which showed a sharp decline in rates of first admission after that age in France. Before the age of 45 first admission rates were much higher in France. Evidence from the survey suggests, on the one hand, that French diagnostic criteria are narrower, as schizophrenia is viewed as a chronic syndrome resulting in deterioration, with exclusion of cases of acute onset or good outcome. On the other hand, however, the French regard the less clearly defined Bleulerian signs,"'7"1 such as "dissociation," as the key symptoms of the disorder, reminiscent of the situation in the United States before the advent of standardised criteria."9 Also, the French have a "pseudopsychopathic" subtype of schizophrenia, not recognised by the British. The French concept of schizophrenia therefore seems to encompass a variety of chronic states that would be excluded in the United Kingdom for lack of specific symptoms.
Some diagnostic drift may have occurred in both countries, but in opposite directions, and this might explain the differences in longitudinal trends observed in both countries. In England there was a proportional increase in the category "other psychoses" over the period under investigation," which may reflect the use of standardised and restrictive criteria for schizophrenia."' In France, a broadening of the concept of schizophrenia might have occurred because of the influence of Jacques Lacan (and other psychoanalysts). Lacan has been considered the mainspring of the "invasion of French intellectual life by psychoanalysis"2' and had a profound influence on the con-BMJ VOLuMEt 307 The prevalence ofrecurrent epilepsy is about 0 5-1 .0%, and slightly less than half of those affected are women. The possibility of pregnancy should be considered in any woman of childbearing age with epilepsy because treatment is likely to be necessary for a minimum of two years and maybe indefinitely. This certainly applies to any girl over the age of 15. Withdrawal of antiepileptic drugs well before a planned pregnancy should be considered because neural tube defects occur before 28 days, but if a patient requires antiepileptic drugs treatment should be continued throughout pregnancy.
In this article we answer the questions commonly asked by epileptic patients regarding contraception and pregnancy. Patients may ask only a few of the questions at one time, but most will appreciate a discussion ofother potential problems.
Contraception COMBINED CONTRACEPTIVE PIL
There is no reason why women with epilepsy taking antiepileptic drugs should not take combined oral contraceptives, which act by giving a sufficient dose of oestrogen to inhibit ovulation. In most women this requires an oral dose of oestrogen above 20 ,ug and the most widely prescribed drugs contain 30 ,ug of oestrogen (Microgynon 30, Eugynon 30, Ovran 30, Ovranette, and Marvelon), giving some measure of safety. The induction of microsomal liver enzyme activity by some antiepileptic drugs (phenytoin, carbamazepine, phenobarbitone, and primidone) increases the rate of metabolism of both oestrogen and progesterone, thereby lowering the blood concentrations of these drugs, often by 50% or more. It is therefore usual to recommend a combined oral contraceptive preparation containing at least 50 ,g of Summary ofmain points * Women taking enzyme inducing antiepileptic drugs should take higher doses of oral contraceptives * Progesterone concentrations should be measured on day 21 ofthe first or second cycle to ensure that ovulation is being suppressed * Risk of fetal abnormalities, especially cleft lip and palate and congenital heart abnormalities, is raised in women taking antiepileptic drugs * Women taking antiepileptic drugs should all have a fetoprotein concentrations measured at 18 weeks and high resolution ultrasonography * Impaired absorption of antiepileptic drugs during pregnancy and increased blood volume may make it necessary to adjust the dose, particularly in women with poorly controlled epilepsy * Vitamin K1 supplements in the last week before delivery help raise fetal plasma con- 
